A new non-dopaminergic drug known as pimavanserin was found to be safe and effective in relieving psychotic symptoms in Parkinson's disease and could be useful for Alzheimer's disease and other similar conditions. The trial, which involved 199 patients with psychotic symptoms associated with Parkinson's, showed that 37% of those who received pimavanserin showed improvement in psychotic symptoms compared with 14% of the placebo group. Details of the Phase III trial were published in The Lancet.

Related Summaries